Key Takeaways
- • Lauxera Capital Partners has closed its second Healthtech growth fund at €400 million, surpassing the initial target and achieving final close in record time, positioning it as a major European player in healthcare venture capital.
- • The fund focuses on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies, with a strategic mandate to help portfolio companies navigate U.S. regulatory complexity and scale operations internationally.
- • Lauxera's previous fund (Growth I) closed at €260 million and backed a dozen high-growth companies, demonstrating a track record of successful deployment in the European healthtech ecosystem before this larger second fund.
- • The firm maintains dual offices in Paris and San Francisco, leveraging transatlantic expertise to support European healthtech companies expanding globally, with recent portfolio activity including investments in companies like BioLamina AB (€17 million) and stakes in digital health platforms.
- • The €400 million fund represents Lauxera's continued bet on European healthcare innovation reaching global scale, with emphasis on impact measurement alongside financial returns through a documented "Triple Aim" investment criteria framework.
Summary
Lauxera Capital Partners, a healthcare-focused growth equity investor with offices in Paris and San Francisco, has completed fundraising for its second Healthtech growth fund at €400 million. The fund closed at its target in record time, reflecting strong institutional confidence in the firm's ability to deploy capital in the European medical technology and digital health sectors.
The fund targets commercial-stage companies across medical devices, digital health platforms, life sciences tools, and healthcare data infrastructure. According to Lauxera's investment mandate, the firm provides hands-on support to portfolio companies navigating complex U.S. regulatory frameworks, scaling commercial operations, and executing international expansion strategies—a critical value-add given the regulatory fragmentation between European and North American healthcare markets.
This second fund follows the successful close of Lauxera Growth I at €260 million, which backed a dozen high-growth companies. The progression from a €260 million to a €400 million fund reflects investor appetite for European healthtech exposure and validation of the firm's investment thesis. Recent portfolio activity includes a €17 million investment in Swedish regenerative medicine company BioLamina AB and strategic growth capital for platforms like Matrix One and Veranex, demonstrating active deployment across the medical technology value chain.
Lauxera's investment approach incorporates both financial returns and measurable impact, utilizing a documented "Triple Aim" framework to assess portfolio company performance against healthcare quality, cost, and access metrics. The transatlantic positioning—with teams in both Paris and San Francisco—allows the firm to serve as a bridge for European healthtech companies seeking to establish U.S. market presence while maintaining European operational headquarters. This dual-geography structure has become increasingly important as European medical device and digital health companies face pressure to achieve global scale and compete with U.S.-based competitors.
The fund targets commercial-stage companies across medical devices, digital health platforms, life sciences tools, and healthcare data infrastructure. According to Lauxera's investment mandate, the firm provides hands-on support to portfolio companies navigating complex U.S. regulatory frameworks, scaling commercial operations, and executing international expansion strategies—a critical value-add given the regulatory fragmentation between European and North American healthcare markets.
This second fund follows the successful close of Lauxera Growth I at €260 million, which backed a dozen high-growth companies. The progression from a €260 million to a €400 million fund reflects investor appetite for European healthtech exposure and validation of the firm's investment thesis. Recent portfolio activity includes a €17 million investment in Swedish regenerative medicine company BioLamina AB and strategic growth capital for platforms like Matrix One and Veranex, demonstrating active deployment across the medical technology value chain.
Lauxera's investment approach incorporates both financial returns and measurable impact, utilizing a documented "Triple Aim" framework to assess portfolio company performance against healthcare quality, cost, and access metrics. The transatlantic positioning—with teams in both Paris and San Francisco—allows the firm to serve as a bridge for European healthtech companies seeking to establish U.S. market presence while maintaining European operational headquarters. This dual-geography structure has become increasingly important as European medical device and digital health companies face pressure to achieve global scale and compete with U.S.-based competitors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.